Skip to main content

Diabetes Device News

Diabetes Devices monitor and help to manage your blood sugar levels to try to stay within the target range, helping prevent complications of diabetes.

BGM    CGM     Injection Pens     Insulin Pumps      AID

A1c cannot capture the whole picture – hypoglycemia, time in range, and quality of life add so much more!
A six-week study of Tandem’s first automated insulin delivery device with Dexcom’s G5 CGM
Third diabetes partnership for Fitbit, focused on integrating activity and sleep data with diabetes data on the phone and watch
Tidepool, the software nonprofit that collects data from diabetes devices, announces a major new project to drive better research and products from real-world data
Ease, comfort, and actionable patterns, but some challenges with insurance coverage
First trial next month, launch expected in 2-3 years; Dexcom CGM included; a big commitment to diabetes tech innovation from an insulin company
The new blood glucose meter features less expensive strips, uploads readings to smartphones, and integrates with mySugr
How diabetes educators see people with diabetes differently – research from the American Association of Diabetes Educators conference
How one court ruling may reverse Medicare’s policy denying coverage of most CGMs
Device Updates from Abbott, Dexcom, Insulet, Medtronic, and Tandem
Expected in 2017. Plus, the latest in the pipeline, including concentrated insulin systems and the Horizon Automated Glucose Control System
Results from the type 2 diabetes group in Dexcom’s DIaMonD trial show A1c and time-in-range benefits
Training to be tested in a small group before the full launch starts in June
What does donated diabetes data tell us about time-in-range across different age groups?
The diaTribe Foundation’s first “Musings After Hours” discussion with leading experts on digital health and tech in diabetes
One Drop Premium and Bluetooth-enabled Chrome meter available in US and EU, as well as 24/7 in-app support
Launch by end of 2017 in major pharmacies at lower price than other CGMs; No fingerstick calibration needed, 10-day wear, 12-hour warmup
People with type 1 or type 2 diabetes on intensive insulin therapy can qualify. A major win for the diabetes community following years of patient advocacy!
With Roche’s support, mySugr will expand to more countries and will even begin offering a new package with unlimited test strips and diabetes coaching through German...
Continuously delivers GLP-1 agonist for 3-6 months; FDA decision is expected by the end of 2017